Altre lingue BioNxt Solutions Inc.

Azioni

BNXT

CA0909741062

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 21:46:40 11/07/2024			Variaz. 5gg	Var. 1 gen.
0,3 ^CAD	+7,14%		+11,11%	-38,14%

29/05	BioNxt Solutions Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
26/04	BioNxt Solutions Inc. annuncia un aggiornamento su Cladribina ODF	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioNxt Solutions Inc.: BioNxt unterzeichnet Dienstleistungs-Rahmenvertrag mit internationaler Organisation für Auftragsforschung, -entwicklung und -herstellung	09/07
BioNxt Solutions Inc. announced that it has received CAD 0.945 million in funding	27/06
BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05
BioNxt Solutions Inc. Announces ODF Cladribine Update	26/04
BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding	26/04
BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/04
BioNxt Solutions Provides Update on Commercialization of ODF Cladribine Product for Multiple Sclerosis	18/03
BioNxt Solutions Inc.: BioNxt berichtet über die nächsten Schritte zur Markteinführung seines Produkts Cladrabine ODF für die Behandlung der Multiplen Sklerose	18/03
BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps	18/03
BioNxt Solutions Reported Results From ODF Cladribine PK Study	13/03
BioNxt Solutions Inc.: BioNxt berichtet über erfolgreiche Ergebnisse aus seiner Pharmakokinetikstudie zu Cladribine ODF	13/03
BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study	13/03
BioNxt Solutions Reports Completion of ODF Cladribine PK Study	04/03
BioNxt Solutions Inc.: BioNxt berichtet über den Abschluss der Pharmakokinetikstudie zu Cladribine ODF	04/03
BioNxt Solutions Finalizes Agreement	19/02
BioNxt Solutions Inc.: BioNxt meldet erfolgreiche Ergebnisse der ODF-Cladribin-Toxizitätsstudie	08/02
BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study	07/02
BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding	29/01
BioNxt Solutions Inc.: BioNxt Solutions gibt Abschluss der Toxizitätsstudie zu Cladribine ODF und Finanzierung bekannt	22/12
BioNxt Solutions Completed Cladribine ODF Toxicity Study and Financing	22/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BioNxt Solutions Inc.

Azioni

BNXT

CA0909741062

Altre lingue

Filtri